Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Cancer Summaries and Commentaries™: Report From Orlando on Advances in the Treatment of MPNs

Release Date: December 23, 2019
Expiration Date: December 23, 2020
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at the 2019 American Society of Hematology Annual Meeting, held in December in Orlando, Florida. Cancer Summaries and Commentaries™: Report From Orlando on Advances in the Treatment of MPNs is an online continuing medical education (CME) activity that facilitates critical assessment and clinical integration of new clinical trial data. The activity reviews a selection of clinically relevant abstracts in myeloproliferative neoplasm presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by an expert perspective that provides insight into how clinicians can apply these findings to clinical practice to improve patient care.

Benefits of Participating

  • Hear from the experts about recent clinical trials in the field of myeloproliferative neoplasms (MPNs) and their impact on clinical practice decision making
  • Identify opportunities to implement emerging treatments for the management of MPNs including polycythemia vera, myelofibrosis, and essential thrombocythemia
  • Explore the efficacy and safety outcomes from ongoing clinical trials in the treatment and management of MPNs

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Audio” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists/hematologists and fellows who treat patients with myeloproliferative neoplasms. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of myeloproliferative neoplasms will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the design, efficacy, and safety of completed and ongoing clinical studies in patients with myeloproliferative neoplasms (MPNs)
  • Explain findings from recently conducted trials that assessed emerging strategies for the treatment and management of MPNs
  • Consider recent clinical trial data in the context of evolving treatment paradigms in the management of patients with MPNs

Faculty, Staff, and Planners’ Disclosures


John Mascarenhas
John Mascarenhas, MD
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Adult Leukemia Program
Leader of Clinical Investigation, Myeloproliferative Disorders Program
Tisch Cancer Institute at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Incyte Corporation, Novartis, Janssen, CTI BioPharma, Promedior, Celgene, Kartos Therapeutics, PharmaEssentia; Consultant: Celgene, Incyte Corporation, Roche, Kartos, PharmaEssentia.

Srdan Verstovsek
Srdan Verstovsek, MD, PhD
Professor of Medicine
United Energy Resources, Inc.
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Chief, Section for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp., Genentech, Blueprint Medicines Corp., Novartis, Sierra Oncology, Pharma Essentia, Astrazeneca, Ital Pharma, Protagonist Therapeutics. Consultant: Constellation, Pragmatist, Sierra, Incyte, Novartis, Celgene.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By